BR112013029834A2 - vacinas individualizadas para câncer - Google Patents

vacinas individualizadas para câncer

Info

Publication number
BR112013029834A2
BR112013029834A2 BR112013029834A BR112013029834A BR112013029834A2 BR 112013029834 A2 BR112013029834 A2 BR 112013029834A2 BR 112013029834 A BR112013029834 A BR 112013029834A BR 112013029834 A BR112013029834 A BR 112013029834A BR 112013029834 A2 BR112013029834 A2 BR 112013029834A2
Authority
BR
Brazil
Prior art keywords
cancer
tumor
vaccines
patient
relates
Prior art date
Application number
BR112013029834A
Other languages
English (en)
Other versions
BR112013029834A8 (pt
Inventor
Bernhard Renard
Cedrik Britten
Jan Diekmann
Johannes Hendrikus De Graaf
John Castle
Martin Löwer
Michael Koslowski
Mustafa Diken
Sebastian Kreiter
Tana Omokoko
Ugur Sahin
Original Assignee
Biontech Ag
Tron Translationale Onkologie An Der Universitäsmedizin Der Johannes Gutenberg Universität Mainz Gem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by Biontech Ag, Tron Translationale Onkologie An Der Universitäsmedizin Der Johannes Gutenberg Universität Mainz Gem filed Critical Biontech Ag
Publication of BR112013029834A2 publication Critical patent/BR112013029834A2/pt
Publication of BR112013029834A8 publication Critical patent/BR112013029834A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)

Abstract

resumo da patente de invenção para: ”vacinas individualizadas para câncer”. a presente invenção se refere ao fornecimento de vacinas, que são específicas para o tumor de um paciente e são potencialmente úteis para imunoterapia de tumor primário bem como metástases tumorais. em um aspecto, a presente invenção se refere a um método para proporcionar uma vacina individualizada para câncer que compreende as etapas: (a) identificar mutações somáticas específica de câncer num espécime de tumor de um paciente com cãncer para proporcionar uma assinatura da mutação do câncer em um paciente, e (b) fornecer uma vacina que caracteriza a assinatura da mutação de câncer obtida na etapa (a). em um outro aspecto, a presente invenção se refere a vacinas que podem ser obtidas pelo referido método.
BR112013029834A 2011-05-24 2012-05-23 vacinas individualizadas para câncer BR112013029834A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
PCT/EP2012/002209 WO2012159754A2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (2)

Publication Number Publication Date
BR112013029834A2 true BR112013029834A2 (pt) 2016-12-06
BR112013029834A8 BR112013029834A8 (pt) 2022-10-18

Family

ID=46148823

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029834A BR112013029834A8 (pt) 2011-05-24 2012-05-23 vacinas individualizadas para câncer

Country Status (22)

Country Link
US (3) US10738355B2 (pt)
JP (5) JP6444171B2 (pt)
CN (3) CN103608033B (pt)
AU (4) AU2012261237B2 (pt)
BR (1) BR112013029834A8 (pt)
CA (1) CA2836494C (pt)
DK (2) DK2714071T3 (pt)
ES (3) ES2946072T3 (pt)
FI (1) FI3892295T3 (pt)
HR (2) HRP20230443T1 (pt)
HU (3) HUE062102T2 (pt)
LT (3) LT3892295T (pt)
MX (2) MX360823B (pt)
NZ (2) NZ742420A (pt)
PL (1) PL3892295T3 (pt)
PT (3) PT3473267T (pt)
RS (2) RS64230B1 (pt)
RU (1) RU2670745C9 (pt)
SG (2) SG193553A1 (pt)
SI (2) SI3473267T1 (pt)
WO (1) WO2012159754A2 (pt)
ZA (1) ZA201306944B (pt)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
DK2387627T3 (en) 2009-01-15 2016-07-04 Adaptive Biotechnologies Corp Adaptive immunity profiling and methods for producing monoclonal antibodies
EP2446052B1 (en) 2009-06-25 2018-08-08 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
BR112013029834A8 (pt) 2011-05-24 2022-10-18 Biontech Ag vacinas individualizadas para câncer
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2858070C (en) 2011-12-09 2018-07-10 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
ES2904816T3 (es) 2012-02-27 2022-04-06 Becton Dickinson Co Composiciones para recuento molecular
DK2823060T3 (en) 2012-03-05 2018-05-28 Adaptive Biotechnologies Corp Determination of associated immune receptor chains from frequency-matched subunits
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2582554T3 (es) 2012-05-08 2016-09-13 Adaptive Biotechnologies Corporation Composiciones y método para medir y calibrar el sesgo de la amplificación en reacciones de PCR multiplexadas
CN104662171B (zh) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
DK2901341T3 (da) 2012-09-28 2019-07-15 Univ Connecticut Identifikation af tumorbeskyttelsesepitoper til behandling af cancere
DK2904111T3 (en) 2012-10-01 2018-03-12 Adaptive Biotechnologies Corp Immune competence evaluation of adaptive immune receptor diversity and clonality characterization
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US10155031B2 (en) * 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014093186A1 (en) * 2012-12-12 2014-06-19 Garvin Alex M Non-invasive detection of colorectal neoplasia using circular consensus sequencing
EP2946345B1 (en) 2013-01-17 2024-04-03 Personalis, Inc. Methods and systems for genetic analysis
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
SG10201707394PA (en) * 2013-03-15 2017-10-30 Adaptive Biotechnologies Corp Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
WO2014168874A2 (en) * 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
WO2015013461A2 (en) * 2013-07-26 2015-01-29 Sequenta, Inc. Cancer vaccination with antigen evolution
GB2546833B (en) 2013-08-28 2018-04-18 Cellular Res Inc Microwell for single cell analysis comprising single cell and single bead oligonucleotide capture labels
EP3039161B1 (en) 2013-08-30 2021-10-06 Personalis, Inc. Methods and systems for genomic analysis
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
GB2535066A (en) 2013-10-03 2016-08-10 Personalis Inc Methods for analyzing genotypes
CN105745528A (zh) 2013-10-07 2016-07-06 赛卢拉研究公司 用于以数字方式对阵列上的特征进行计数的方法和***
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
DK3077539T3 (en) 2013-12-02 2018-11-19 Personal Genome Diagnostics Inc Procedure for evaluating minority variations in a sample
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2932798C (en) * 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
AU2015227054A1 (en) 2014-03-05 2016-09-22 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3132059B1 (en) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
JP7044551B2 (ja) 2014-09-10 2022-03-30 ジェネンテック， インコーポレイテッド 免疫原性変異体ペプチドスクリーニングプラットフォーム
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016053339A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
ES2784343T3 (es) 2014-10-29 2020-09-24 Adaptive Biotechnologies Corp Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras
EP3212808B1 (en) 2014-10-30 2022-03-02 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016134078A1 (en) * 2015-02-19 2016-08-25 Becton, Dickinson And Company High-throughput single-cell analysis combining proteomic and genomic information
EP3262196B1 (en) 2015-02-24 2020-12-09 Adaptive Biotechnologies Corp. Method for determining hla status using immune repertoire sequencing
EP3261605B2 (en) 2015-02-26 2022-04-20 SiO2 Medical Products, Inc. Cycloolefin polymer container with a scratch resistant and anti-static coating
WO2016138496A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
ES2934982T3 (es) 2015-03-30 2023-02-28 Becton Dickinson Co Métodos para la codificación con códigos de barras combinatorios
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
EP3286326A1 (en) 2015-04-23 2018-02-28 Cellular Research, Inc. Methods and compositions for whole transcriptome amplification
MX2017013777A (es) * 2015-04-27 2018-03-27 Cancer Research Tech Ltd Metodo para el tratamiento de cancer.
US10568948B2 (en) * 2015-05-13 2020-02-25 Agenus Inc. Vaccines for treatment and prevention of cancer
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
US11124823B2 (en) 2015-06-01 2021-09-21 Becton, Dickinson And Company Methods for RNA quantification
TWI750122B (zh) * 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3328394A4 (en) * 2015-07-30 2019-03-13 ModernaTX, Inc. PEPTIDE CONCATEMERIC EPITAOPE RNA
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017044574A1 (en) 2015-09-11 2017-03-16 Cellular Research, Inc. Methods and compositions for nucleic acid library normalization
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
EP3362103A4 (en) * 2015-10-12 2020-02-05 Nantomics, LLC COMPOSITIONS AND METHODS USING VIRAL CANCER NEOEPITOPES
EP3362929B1 (en) * 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
CA3003090A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
AU2016369519B2 (en) 2015-12-16 2023-04-20 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
CN105349533A (zh) * 2015-12-21 2016-02-24 生工生物工程（上海）股份有限公司 构建链特异性转录组文库的方法
KR20180100659A (ko) * 2016-01-08 2018-09-11 백시바디 에이에스 치료적 항암 네오에피토프 백신
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
CN109563521A (zh) 2016-03-24 2019-04-02 河谷细胞有限公司 用于新表位呈递的序列排列和序列
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US20190343942A1 (en) * 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen
EP4269616A3 (en) 2016-05-02 2024-02-14 Becton, Dickinson and Company Accurate molecular barcoding
WO2017190242A1 (en) * 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
EP3465502B1 (en) 2016-05-26 2024-04-10 Becton, Dickinson and Company Molecular label counting adjustment methods
CA3025648A1 (en) * 2016-05-27 2017-11-30 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
WO2018011289A1 (en) * 2016-07-13 2018-01-18 Vaximm Ag Process for the production of a dna vaccine for cancer immunotherapy
AU2017299162A1 (en) * 2016-07-20 2019-02-07 BioNTech SE Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
AU2017331459B2 (en) 2016-09-26 2023-04-13 Becton, Dickinson And Company Measurement of protein expression using reagents with barcoded oligonucleotide sequences
US11164659B2 (en) 2016-11-08 2021-11-02 Becton, Dickinson And Company Methods for expression profile classification
CN117056774A (zh) 2016-11-08 2023-11-14 贝克顿迪金森公司 用于细胞标记分类的方法
WO2018089637A1 (en) 2016-11-11 2018-05-17 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
CN108090325B (zh) * 2016-11-23 2022-01-25 中国科学院昆明动物研究所 一种应用β-稳定性分析单细胞测序数据的方法
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
ES2961580T3 (es) 2017-01-13 2024-03-12 Cellular Res Inc Revestimiento hidrófilo de canales de fluidos
ES2971298T3 (es) * 2017-01-18 2024-06-04 Icahn School Med Mount Sinai Neoantígenos y usos de los mismos para el tratamiento del cáncer
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP2020506189A (ja) * 2017-02-01 2020-02-27 モデルナティーエックス， インコーポレイテッド Ｒｎａ癌ワクチン
CN110430894A (zh) * 2017-02-01 2019-11-08 莫得纳特斯公司 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
US11319583B2 (en) 2017-02-01 2022-05-03 Becton, Dickinson And Company Selective amplification using blocking oligonucleotides
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
US11938153B2 (en) 2017-03-31 2024-03-26 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
AU2018258119B2 (en) 2017-04-24 2021-04-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
CA3062883C (en) 2017-05-11 2024-04-02 Theralase Biotech, Inc. Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
CA3059559A1 (en) 2017-06-05 2018-12-13 Becton, Dickinson And Company Sample indexing for single cells
WO2018224166A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
IL271558B2 (en) 2017-06-21 2024-01-01 Transgene A vaccine tailored to the individual
MX2020000414A (es) * 2017-07-12 2020-09-28 Nouscom Ag Composicion de vacuna de neoantigeno para el tratamiento del cancer.
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
US20200354730A1 (en) * 2017-11-27 2020-11-12 Nantcell, Inc. Improved Yeast Polytope Vaccine Compositions And Methods
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
TWI727232B (zh) * 2017-12-01 2021-05-11 大陸商上海桀蒙生物技術有限公司 個人化癌症疫苗的製備方法
CA3083792A1 (en) * 2017-12-18 2019-06-27 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2019126209A1 (en) 2017-12-19 2019-06-27 Cellular Research, Inc. Particles associated with oligonucleotides
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
EP3766075A1 (en) * 2018-03-14 2021-01-20 Koninklijke Philips N.V. System and method using local unique features to interpret transcript expression levels for rna sequencing data
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
US11365409B2 (en) 2018-05-03 2022-06-21 Becton, Dickinson And Company Molecular barcoding on opposite transcript ends
US11773441B2 (en) 2018-05-03 2023-10-03 Becton, Dickinson And Company High throughput multiomics sample analysis
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neo-antigens
CN112261947A (zh) * 2018-05-25 2021-01-22 威斯塔研究所 肿瘤特异性新抗原和其使用方法
CN108897986B (zh) * 2018-05-29 2020-11-27 中南大学 一种基于蛋白质信息的基因组序列拼接方法
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
EP3813848A4 (en) * 2018-06-27 2022-07-20 ModernaTX, Inc. EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
JP2022511398A (ja) 2018-10-01 2022-01-31 ベクトン・ディキンソン・アンド・カンパニー ５’転写物配列の決定
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CN114573688A (zh) * 2018-10-19 2022-06-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
US20220125899A1 (en) * 2018-11-07 2022-04-28 Modernatx, Inc. Rna cancer vaccines
EP3877520A1 (en) 2018-11-08 2021-09-15 Becton Dickinson and Company Whole transcriptome analysis of single cells using random priming
US20210379170A1 (en) * 2018-11-15 2021-12-09 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
CN113195717A (zh) 2018-12-13 2021-07-30 贝克顿迪金森公司 单细胞全转录组分析中的选择性延伸
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007556A (es) * 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
US11371076B2 (en) 2019-01-16 2022-06-28 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
WO2020154247A1 (en) 2019-01-23 2020-07-30 Cellular Research, Inc. Oligonucleotides associated with antibodies
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20220160850A1 (en) * 2019-02-15 2022-05-26 Rjan Holding Ab Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine
EP3940073A4 (en) 2019-03-13 2023-03-01 Toyobo Co., Ltd. PRODUCTION AND AMPLIFICATION OF NUCLEIC ACIDS
US11965208B2 (en) 2019-04-19 2024-04-23 Becton, Dickinson And Company Methods of associating phenotypical data and single cell sequencing data
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
US11939622B2 (en) 2019-07-22 2024-03-26 Becton, Dickinson And Company Single cell chromatin immunoprecipitation sequencing assay
CN110277135B (zh) * 2019-08-10 2021-06-01 杭州新范式生物医药科技有限公司 一种基于预期疗效选择个体化肿瘤新抗原的方法和***
TWI793451B (zh) * 2019-09-20 2023-02-21 納維再生科技股份有限公司 個人化癌症免疫治療
CN114729350A (zh) 2019-11-08 2022-07-08 贝克顿迪金森公司 使用随机引发获得用于免疫组库测序的全长v(d)j信息
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
AU2020403145A1 (en) 2019-12-13 2022-07-07 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
CN115244184A (zh) 2020-01-13 2022-10-25 贝克顿迪金森公司 用于定量蛋白和rna的方法和组合物
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
US11661625B2 (en) 2020-05-14 2023-05-30 Becton, Dickinson And Company Primers for immune repertoire profiling
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11739443B2 (en) 2020-11-20 2023-08-29 Becton, Dickinson And Company Profiling of highly expressed and lowly expressed proteins
JP2024501482A (ja) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023085232A1 (ja) 2021-11-10 2023-05-19 東洋紡株式会社 改良されたライブラリー調製方法
CN114181287B (zh) * 2021-12-10 2023-09-19 商丘美兰生物工程有限公司 一种dna病毒疫苗的制备方法
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114410778B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
KR20230130804A (ko) * 2022-03-04 2023-09-12 (주)큐리진 순환종양세포 검출을 위한 아데노바이러스 5/3 형
EP4253550A1 (en) 2022-04-01 2023-10-04 GenCC GmbH 6 Co. KG Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes
WO2023209068A1 (en) 2022-04-28 2023-11-02 Carbocalyx Gmbh Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064931A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
DK0895538T3 (da) * 1996-04-19 2002-11-04 Us Gov Sec Health Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter
EP0900380B1 (en) 1996-04-26 2003-07-09 Rijksuniversiteit te Leiden Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
WO1998010748A1 (en) 1996-09-13 1998-03-19 The School Of Pharmacy Liposomes
KR20000049096A (ko) * 1996-10-11 2000-07-25 린다 에스. 스티븐슨 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
WO1999024566A1 (en) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO1999034014A2 (en) 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
WO1999034015A2 (en) * 1997-12-24 1999-07-08 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
JP2002526421A (ja) 1998-10-05 2002-08-20 ジェンザイム・コーポレーション 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
US6500641B1 (en) 1999-05-06 2002-12-31 Wake Forest University School Of Medicine Compositions and methods for identifying antigens which elicit an immune response
JP2003509035A (ja) 1999-09-16 2003-03-11 ザイコス インク． ポリエピトープポリペプチドをコードする核酸
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
WO2001047959A2 (en) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2001093902A2 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
EP1800697B1 (de) 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
WO2003046189A1 (en) 2001-11-26 2003-06-05 The University Of Queensland Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003059381A2 (en) 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
AU2002254010A1 (en) * 2002-02-19 2003-09-09 Genzyme Corporation Par-3 compounds for therapy and diagnosis and methods for using same
EP1485403A4 (en) * 2002-03-15 2007-08-08 Multicell Immunotherapeutics I COMPOSITIONS AND METHOD FOR INTRODUCTION OR REINFORCEMENT OF ANTIBODY AND MAIN THISTOCOMPATIBILITY CLASS I OR CLASS II RESTRICTED T-CELL REACTIONS USING IMMUNOMODULATING, NON-CODING RNA MOTIVES
ES2370688T3 (es) 2002-06-13 2011-12-21 Merck Patent Gmbh Métodos para la identificación de alo-antígenos y su utilización para la terapia contra el cáncer y para el trasplante.
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20080063699A1 (en) 2003-10-15 2008-03-13 Michael Teifel Method of Administering Cationic Liposomes Comprising an Active Drug
ATE490470T1 (de) 2003-10-24 2010-12-15 Immunaid Pty Ltd Therapieverfahren
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
SG158155A1 (en) 2004-12-29 2010-01-29 Mannkind Corp Methods to bypass cd+4 cells in the induction of an immune response
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
LT2578685T (lt) 2005-08-23 2019-06-10 The Trustees Of The University Of Pennsylvania Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2007101227A2 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
CA2647280A1 (en) 2006-03-13 2007-09-20 Veridex, Llc Propagation of primary cells
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2061504A4 (en) 2006-09-20 2010-01-27 Univ Johns Hopkins COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
JP5623747B2 (ja) 2006-12-27 2014-11-12 エモリー ユニバーシティ 感染症および腫瘍を処置するための組成物および方法
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
DK2386557T3 (en) 2008-03-24 2018-04-23 Biontech Ag Newly substituted imidazoquinolines
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP5268444B2 (ja) * 2008-06-23 2013-08-21 株式会社日立ハイテクノロジーズ 単分子リアルタイムシーケンス装置，核酸分析装置及び単分子リアルタイムシーケンス方法
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010042919A2 (en) 2008-10-11 2010-04-15 Government Of The U.S.A. , As Represented By The Secretary, Dpartmetn Of Health And Human Services Method of making a vaccine
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2459231B1 (de) 2009-07-31 2016-06-08 Ethris Gmbh Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
ES2788863T3 (es) * 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
BR112013029834A8 (pt) 2011-05-24 2022-10-18 Biontech Ag vacinas individualizadas para câncer
RS59369B1 (sr) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizovane vakcine protiv kancera
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
WO2013106496A1 (en) 2012-01-10 2013-07-18 modeRNA Therapeutics Methods and compositions for targeting agents into and across the blood-brain barrier
US9321808B2 (en) 2012-02-20 2016-04-26 Biontech Ag Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
CN104662171B (zh) 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
AU2013337651B2 (en) 2012-11-01 2018-12-13 Factor Bioscience Inc. Methods and products for expressing proteins in cells
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
WO2014168874A2 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3043826A4 (en) 2013-09-13 2017-05-24 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
JP6363179B2 (ja) 2013-09-26 2018-07-25 バイオンテック アーゲー Ｒｎａによるシェルを含む粒子
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US20160264614A1 (en) 2013-10-02 2016-09-15 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170007776A1 (en) 2014-02-05 2017-01-12 Biontech Ag Cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
EP3240558A1 (en) 2014-12-30 2017-11-08 CureVac AG Artificial nucleic acid molecules
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Also Published As

Publication number Publication date
LT2714071T (lt) 2019-10-10
HUE062102T2 (hu) 2023-09-28
CN105999250B (zh) 2020-03-10
PT2714071T (pt) 2019-09-30
JP2017018129A (ja) 2017-01-26
NZ718326A (en) 2020-05-29
AU2022201275A1 (en) 2022-03-17
US11248264B2 (en) 2022-02-15
CN111286537A (zh) 2020-06-16
SG10201911616QA (en) 2020-01-30
RU2670745C9 (ru) 2018-12-13
CN103608033B (zh) 2016-06-15
HRP20230443T1 (hr) 2023-09-15
JP2019050831A (ja) 2019-04-04
MX2013013659A (es) 2014-02-27
JP6456888B2 (ja) 2019-01-23
CA2836494A1 (en) 2012-11-29
AU2019229434B2 (en) 2021-12-16
CN103608033A (zh) 2014-02-26
ES2946072T3 (es) 2023-07-12
MX2020011767A (es) 2020-11-24
BR112013029834A8 (pt) 2022-10-18
JP6444171B2 (ja) 2018-12-26
NZ617217A (en) 2016-04-29
JP7297715B2 (ja) 2023-06-26
RU2013157150A (ru) 2015-06-27
US10738355B2 (en) 2020-08-11
JP2014523406A (ja) 2014-09-11
LT3892295T (lt) 2023-07-10
RU2670745C2 (ru) 2018-10-25
AU2017213515B2 (en) 2019-07-04
DK2714071T3 (da) 2019-09-16
CA2836494C (en) 2023-01-03
SI3892295T1 (sl) 2023-09-29
US20220282322A1 (en) 2022-09-08
PT3473267T (pt) 2021-11-02
DK3892295T3 (da) 2023-05-15
FI3892295T3 (fi) 2023-05-10
AU2012261237B2 (en) 2017-06-01
NZ730355A (en) 2022-10-28
PL3892295T3 (pl) 2023-07-24
JP2020128423A (ja) 2020-08-27
ES2746233T3 (es) 2020-03-05
HUE057608T2 (hu) 2022-06-28
RS62497B1 (sr) 2021-11-30
JP2023083289A (ja) 2023-06-15
NZ742420A (en) 2022-10-28
CN105999250A (zh) 2016-10-12
AU2017213515A1 (en) 2017-08-31
MX360823B (es) 2018-11-16
WO2012159754A3 (en) 2013-06-27
US20210164034A1 (en) 2021-06-03
AU2012261237A1 (en) 2013-11-14
SG193553A1 (en) 2013-10-30
PT3892295T (pt) 2023-06-01
HRP20211595T1 (hr) 2022-01-21
ES2746233T8 (es) 2020-03-13
SI3473267T1 (sl) 2022-01-31
US20140178438A1 (en) 2014-06-26
RS64230B1 (sr) 2023-06-30
WO2012159754A2 (en) 2012-11-29
AU2019229434A1 (en) 2019-10-03
ES2897656T3 (es) 2022-03-02
HUE046152T2 (hu) 2020-02-28
ZA201306944B (en) 2015-02-25
LT3473267T (lt) 2021-11-25

Similar Documents

Publication Publication Date Title
BR112013029834A2 (pt) vacinas individualizadas para câncer
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BR112017020893A2 (pt) método para o tratamento de câncer
CY1121934T1 (el) Αντισωματα anti-fcrn
CU20200089A7 (es) Moléculas de unión contra bcma
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
CY1120866T1 (el) Παρεμποδιστες dna-pk
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
BR112015027291A2 (pt) entrega de imunossupressores que têm uma vida eficaz farmacodinâmica especificada e antígeno para a indução de tolerância imunológica
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
BR112015027743B8 (pt) métodos para preparar frações de lignina termicamente estáveis
BR112016028219A2 (pt) composto, método de tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo, método de tratamento ou prevenção de leucemia, câncer de pulmão de não pequenas células, carcinoma hepatocelular, ou glioblastomas em um indivíduo, método de tratamento de uma doença ou distúrbio em um indivíduo, composição farmacêutica e processo para obtenção de um composto de fórmula (i)
BR112016001611A2 (pt) Anticorpos multiespecíficos, anticorpos ativáveis multiespecíficos e métodos de utilização dos mesmos
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
DOP2013000280A (es) Proteínas de unión a antígeno
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
AR089467A1 (es) Hidrogeles de silicona que se forman a partir de mezclas reactivas de diluyente cero
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
BR112015031278A8 (pt) compostos e nanopartículas de platina com base em lipídio
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
BR112015030229A2 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112015021189A2 (pt) métodos de banco de células de alta densidade
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
CY1123698T1 (el) Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: BIONTECH AG (DE) , TRON - TRANSLATIONALE ONKOLOGIE

B25A Requested transfer of rights approved

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAE

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; BIONTECH SE (DE)